crizotinib and Arrhythmias--Cardiac

crizotinib has been researched along with Arrhythmias--Cardiac* in 1 studies

Other Studies

1 other study(ies) available for crizotinib and Arrhythmias--Cardiac

Article	Year
Crizotinib-induced simultaneous multiple cardiac toxicities. Investigational new drugs, 2018, Volume: 36, Issue:5 Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed. Topics: Adenocarcinoma; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiotoxicity; Crizotinib; Female; Humans; Long QT Syndrome; Lung Neoplasms; Middle Aged; Pericarditis; Protein Kinase Inhibitors; Proto-Oncogene Mas	2018

Article

Year

Crizotinib-induced simultaneous multiple cardiac toxicities.

Investigational new drugs, 2018, Volume: 36, Issue:5

Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed.

Topics: Adenocarcinoma; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiotoxicity; Crizotinib; Female; Humans; Long QT Syndrome; Lung Neoplasms; Middle Aged; Pericarditis; Protein Kinase Inhibitors; Proto-Oncogene Mas

2018